Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

e the long-term safety of pirfenidone in patients with IPF. ITMN-191 (R7227): -- In November 2008, Roche, InterMune and Pharmasset, Inc. initiated the first all-oral combination study of direct anti-virals in the absence of interferon or ribavirin, known as the INFORM-1 study. That study has completed the first dose cohort. -- On January 12, 2009, InterMune announced top-line results from a 14-day, Phase 1b study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). - After 14 days of triple combination therapy, the median change in HCV RNA from baseline exceeded 5 log10 in five of the six dosage cohorts in the study, and was -5.4 log10 and -5.7 log10 in the best performing q12h and q8h cohorts, respectively. - Reductions in HCV RNA occurred rapidly and there was no evidence of viral rebound during ITMN-191 treatment in any cohort. - ITMN-191 was generally safe and well tolerated in the study. There were no serious adverse events or Grade 4 adverse events (AEs) during treatment with ITMN-191. AEs reported during study treatment (ITMN-191 or placebo) were predominantly mild to moderate in severity, typically consistent with the AE profile of standard of care (SOC), and none led to treatment discontinuation. Financial: -- On February 19, 2009, InterMune completed a follow-on public offering of 4,025,000 shares of common stock, including the underwriters' over-allotment, at an offer price of $16.35 per share. Net proceeds to InterMune were approximately $63.5 million after deduction of underwriting fees and other related expenses. -- The Medicines Company announced on February 25, 2009, that it had completed its tender offer for all of the outstanding shares of Targanta Therapeutics Co
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... pharmaceutical market is one of the most attractive in ... size, plus a growing economy and increasing government investment ... International. The Russian market is set to grow at ... growth estimates around 10-15% annually reaching an approximate market ... Green Cross Green Cross provides total healthcare ...
(Date:3/25/2015)... Optimal Research, LLC has been nominated as ... "Best Clinical Site or Trial Network". This ... selected as a nominee in this ViE award category ... distinction in 2014. The ViE awards were created to ... positive contributions of companies and individuals in the vaccine ...
(Date:3/25/2015)... March 25, 2015 Laboratory workers ... Balances and Analytical Balances to get best-performing features ... of weighing balances from the trusted brand include: ... increase your efficiency by providing a large ... samples. Weighing modes include parts counting, percent weighing, ...
(Date:3/25/2015)... An increase of awareness related to benefits ... food nutrients, regulatory changes and concerns related to consumer ... for natural astaxanthin over the past few years. Producers ... capacities to satisfy the rising demand. , The ... (used in nutraceuticals, aqua feed, food and beverages and ...
Breaking Biology Technology:Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2
... Kan., Nov. 16, 2011 The Kansas Bioscience Authority ... ended June 30, and cumulative outcomes since the KBA,s ... investments, are reported annually based on information provided by ... full-time jobs created by bioscience companies in Kansas; ...
... Livestream Info ... http://thehill.com/video/in-the-news/193083-livestreaming-genetic-testing-briefing . , ... is redefining cancer treatment, and the pace of discovery promises ... conditions. That will be among the topics of discussion today ...
... 2011 Nektar Therapeutics (NASDAQ: NKTR ... a next-generation topoisomerase I inhibitor, at the 2011 ... being held in San Francisco, California.  The preclinical ... pegylated liposomal doxorubicin (PLD) in vivo has strong ...
Cached Biology Technology:Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million 2Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million 3Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer 2NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 2NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 3NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 4NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 5NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer 6
(Date:3/11/2015)... , March 11, 2015   The ... its platform to scientifically measure and harness music ... to real-time biometrics and objective measurements of physiology, ... music at scale in large populations. It is ... technologists and clinicians perform rigorous studies and accelerate ...
(Date:3/5/2015)... In Brazil , cloud computing ... these solutions and 42 percent planning to invest in them ... percent of the companies will be investing in these solutions ... companies in the region are currently opting for the private ... command significant attention in the coming years. This trend is ...
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , ... today introduced the SentiGaze Software Development Kit ... create applications that use off-the-shelf webcams to track eye ... gazes at a monitor. Heatmaps can be used for ... effectiveness of online advertising. The SDK can also be ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... events, two comprehensive, collaborative projects that include the work ... Natural History will grace the covers of the journals ... Science, herpetologist and Associate Dean of Science Christopher Raxworthy ... more typical few keystone species, to determine a conservation ...
... be so old that dinosaurs once lumbered along its rim, ... Colorado at Boulder and the California Institute of Technology. ... show the Grand Canyon may have formed more than 55 ... million to 50 million years. The researchers gathered evidence ...
... the evolutionary history of animals indicates that Earth,s first ... from fossils and studies of living animals--was probably significantly ... which was funded by the National Science Foundation (NSF), ... issue of Nature. Using new high-powered technologies for analyzing ...
Cached Biology News:AMNH scientists grace Science & Nature covers 2AMNH scientists grace Science & Nature covers 3Grand Canyon may be as old as dinosaurs, says new study 2Grand Canyon may be as old as dinosaurs, says new study 3And the first animal on Earth was a... 2And the first animal on Earth was a... 3
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... contain a proprietary high-performance desalting resin, exclusive ... protein-recovery characteristics compared to other commercially available ... g/ml of protein can be processed, providing ... of salts and other small molecules ( ...
Biology Products: